This is a multicentre retrospective study of 51 eyes that received intravitreal ocriplasmin between January 2013 to January 2014 for symptomatic vitreomacular (VMT) +/- macular hole (MH), and then went on to PPV for persistent pathology, comparing a control group of 22 eyes which preceded directly to PPV. VA was better at all time points in the PPV only group compared to the Ocriplasmin-treated group, at three and six months after PPV. Both groups had similar amount of visual improvement. Both groups had similar rates of apthology resolution; 50/51 (98%) eyes in the ocriplasmin group and 22/22 (100%) in the PPV only group had release of VMT and / or MH closure after PPV. Similar rates of PPV related complications were noted in both groups. The authors mentioned the retrospective nature, small size sample, limited follow-up duration, differences in baseline features between the groups, and phakic eyes were not excluded in the study.